Global Neuromuscular Diseases Therapeutics Market 2019-2023 | 14% CAGR Projection Over the Next Five Years | Technavio

LONDON–(BUSINESS WIRE)–#Biotechnology–The global neuromuscular diseases therapeutics market size is poised to grow by USD 6.05 billion during 2019-2023, according to a new report by Technavio, progressing at a CAGR of more than 14% during the forecast period.

Read the 134-page research report with TOC on “Neuromuscular Diseases Therapeutics Market Analysis Report by type (biologics and small molecules), and geography (North America, Europe, Asia, and ROW) 2019 – 2023”. Request a Free Sample Report.

The market is driven by novel approvals. In addition, the huge unmet need for neuromuscular diseases therapeutics to further boost the growth of the market.

The neuromuscular diseases therapeutics market has been witnessing a number of approvals of novel therapeutics for the treatment of various indications. This is mainly due to advanced research being conducted on highly morbid and progressive indications. Spinal muscular atrophy is one of the major neuromuscular diseases for which the market has witnessed therapeutic approvals. Some of the drugs that recently got approval for the treatment of spinal muscular atrophy include SPINRAZA by Biogen and ZOLGENSMA by Novartis. Therefore, the novel drug approvals are expected to fuel the global neuromuscular diseases therapeutics market growth during the forecast period.

Although many novel drugs have been approved for the treatment of neuromuscular diseases, the market still witnesses a huge unmet need for drugs that are safe and effective. Thus, several vendors are conducting research on developing novel therapeutics, such as disease-modifying drugs, which can treat the complex nature of neuromuscular diseases. Thus, the high unmet need for therapeutics will create huge opportunities for vendors to come up with novel drugs, thereby fueling the market growth during the forecast period.

For More Information: Request for FREE Sample.

The report includes detailed profiles of the leading companies & prominent vendors of the market:

  • Biogen Inc.
  • Novartis AG
  • PTC Therapeutics Inc.
  • Sanofi

Market Segmentation by Type:

The neuromuscular diseases therapeutics market can be broadly categorized into the following segments:

  • Biologics
  • Small Molecules

Key Regions for the Neuromuscular Diseases Therapeutics Market:

Featuring a breakdown of region-wise market shares until 2019.

  • North America
  • Europe
  • Asia
  • ROW

Some of the key topics covered in the report include:

Market Landscape

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis 

Market Sizing

  • Market definition
  • Market size and forecast

Vendor Landscape

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Competitive scenario

Technavio’s sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report.

Related Reports on Information Technology are:

Ophthalmology Therapeutics Market – Global Ophthalmology Therapeutics Market by product (retinal disorder therapeutics, glaucoma therapeutics, dry eye syndrome therapeutics, eye infections and inflammation therapeutics, and other therapeutics) and geography (Asia, Europe, North America, and ROW).

Atherosclerosis Therapeutics Market – Global Atherosclerosis Therapeutics Market by product (small molecules and biologics) and geography (Asia, Europe, North America, and ROW).

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at [email protected].


Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200


Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.